{"transactions":[{"id":1185019,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2025-04-02T20:18:50.000Z","date":"2025-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":7525,"price":7.5,"value":56437.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":377318,"source":{"system":"sec-edgar","filing":"0001127602-25-011136","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760225011136/form4.xml","form_type":"4"}},{"id":1323464,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2024-12-23T21:15:26.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":260950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":260950,"derivative":{"exercise_price":7.39,"exercise_date":"2025-12-19","expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":260950},"source":{"system":"sec-edgar","filing":"0001127602-24-029969","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029969/form4.xml","form_type":"4"}},{"id":1323463,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2024-12-23T21:15:26.000Z","date":"2024-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":6096,"price":7.39,"value":45049.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person."}],"balance_after":384843,"source":{"system":"sec-edgar","filing":"0001127602-24-029969","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029969/form4.xml","form_type":"4"}},{"id":1323462,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2024-12-23T21:15:26.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":125950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":390939,"source":{"system":"sec-edgar","filing":"0001127602-24-029969","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029969/form4.xml","form_type":"4"}},{"id":1329826,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2024-12-17T21:03:21.000Z","date":"2024-12-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":7150,"price":7.53,"value":53839.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person."}],"balance_after":264989,"source":{"system":"sec-edgar","filing":"0001127602-24-029566","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029566/form4.xml","form_type":"4"}},{"id":1516575,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2024-05-15T11:17:30.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":5.86,"value":175800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.84 to $5.86. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."}],"balance_after":272139,"source":{"system":"sec-edgar","filing":"0001127602-24-015371","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224015371/form4.xml","form_type":"4"}},{"id":1554985,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2024-04-02T20:21:52.000Z","date":"2024-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":7525,"price":5.08,"value":38227.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":242139,"source":{"system":"sec-edgar","filing":"0001127602-24-011832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224011832/form4.xml","form_type":"4"}},{"id":1650478,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:47:26.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001104659-24-014717","document":"tm245865-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014717/tm245865-14_4seq1.xml","form_type":"4"}},{"id":1650477,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:47:26.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":32066},"source":{"system":"sec-edgar","filing":"0001104659-24-014717","document":"tm245865-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014717/tm245865-14_4seq1.xml","form_type":"4"}},{"id":1650476,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:47:26.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.97,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-014717","document":"tm245865-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014717/tm245865-14_4seq1.xml","form_type":"4"}},{"id":1650475,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-02-12T16:47:26.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40932,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit (\"DSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":40932},"source":{"system":"sec-edgar","filing":"0001104659-24-014717","document":"tm245865-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014717/tm245865-14_4seq1.xml","form_type":"4"}},{"id":1650474,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:47:26.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13090,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001104659-24-014717","document":"tm245865-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014717/tm245865-14_4seq1.xml","form_type":"4"}},{"id":1650473,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T16:47:26.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3074,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-014717","document":"tm245865-14_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014717/tm245865-14_4seq1.xml","form_type":"4"}},{"id":1694990,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T17:42:48.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":252,"price":29.65,"value":7471.8,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended December 31, 2023."}],"balance_after":3074,"source":{"system":"sec-edgar","filing":"0001415889-24-000372","document":"form4-01032024_100139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924000372/form4-01032024_100139.xml","form_type":"4"}},{"id":1703752,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2023-12-20T21:42:30.000Z","date":"2023-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":5580,"price":6.05,"value":33759.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":249664,"source":{"system":"sec-edgar","filing":"0001127602-23-030189","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223030189/form4.xml","form_type":"4"}},{"id":1708120,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2023-12-18T21:47:02.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":238000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":238000,"derivative":{"exercise_price":6.43,"exercise_date":"2024-12-14","expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":238000},"source":{"system":"sec-edgar","filing":"0001127602-23-029839","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029839/form4.xml","form_type":"4"}},{"id":1708119,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2023-12-18T21:47:02.000Z","date":"2023-12-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":3031,"price":6.43,"value":19489.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":255244,"source":{"system":"sec-edgar","filing":"0001127602-23-029839","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029839/form4.xml","form_type":"4"}},{"id":1708118,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2023-12-18T21:47:02.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":258275,"source":{"system":"sec-edgar","filing":"0001127602-23-029839","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029839/form4.xml","form_type":"4"}},{"id":1771038,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T17:07:22.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":472,"price":15.87,"value":7490.64,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended September 30, 2023."}],"balance_after":2822,"source":{"system":"sec-edgar","filing":"0001415889-23-013759","document":"form4-10022023_091016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923013759/form4-10022023_091016.xml","form_type":"4"}},{"id":1838225,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T17:52:48.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":397,"price":18.87,"value":7491.39,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 for services performed for the quarter ended June 30, 2023."}],"balance_after":2350,"source":{"system":"sec-edgar","filing":"0001415889-23-010819","document":"form4-07052023_090742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923010819/form4-07052023_090742.xml","form_type":"4"}},{"id":1853420,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T16:50:13.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":19597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":19597,"derivative":{"exercise_price":17.72,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19597},"source":{"system":"sec-edgar","filing":"0001415889-23-009953","document":"form4-06162023_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009953/form4-06162023_080610.xml","form_type":"4"}},{"id":1853419,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-06-16T16:50:13.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":13090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date."}],"balance_after":13090,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13090},"source":{"system":"sec-edgar","filing":"0001415889-23-009953","document":"form4-06162023_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923009953/form4-06162023_080610.xml","form_type":"4"}},{"id":1925903,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2023-04-05T20:33:31.000Z","date":"2023-04-03","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":8.29,"value":58030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 25,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.24 to $8.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":207275,"source":{"system":"sec-edgar","filing":"0001127602-23-012587","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223012587/form4.xml","form_type":"4"}},{"id":1930597,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T16:54:06.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":1953,"price":3.84,"value":7499.52,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended December 15, 2022 for services performed for the quarter ended March 31, 2023."}],"balance_after":1953,"source":{"system":"sec-edgar","filing":"0001415889-23-006063","document":"form4-04042023_080459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923006063/form4-04042023_080459.xml","form_type":"4"}},{"id":2079147,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-12-21T21:41:02.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":238000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":238000,"derivative":{"exercise_price":10.63,"exercise_date":"2023-12-19","expiration_date":"2032-12-19","underlying":"Common Stock","underlying_shares":238000},"source":{"system":"sec-edgar","filing":"0001127602-22-028082","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028082/form4.xml","form_type":"4"}},{"id":2079146,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2022-12-21T21:41:02.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":214275,"source":{"system":"sec-edgar","filing":"0001127602-22-028082","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028082/form4.xml","form_type":"4"}},{"id":2082613,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2022-12-19T21:58:08.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":3125,"price":10.89,"value":34031.25,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 11,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":133275,"source":{"system":"sec-edgar","filing":"0001127602-22-027887","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222027887/form4.xml","form_type":"4"}},{"id":2228946,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T16:09:00.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":32066,"price":3.37,"value":108062.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":32066,"derivative":{"exercise_price":3.37,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":32066},"source":{"system":"sec-edgar","filing":"0001415889-22-006706","document":"form4-06172022_010634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006706/form4-06172022_010634.xml","form_type":"4"}},{"id":2228945,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-06-17T16:09:00.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":10932,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The deferred share units vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":40932,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":10932},"source":{"system":"sec-edgar","filing":"0001415889-22-006706","document":"form4-06172022_010634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922006706/form4-06172022_010634.xml","form_type":"4"}},{"id":2309721,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2022-04-04T20:32:37.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":7600,"price":16.2,"value":123120.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares sold to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.09 to $16.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":136400,"source":{"system":"sec-edgar","filing":"0001127602-22-011188","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222011188/form4.xml","form_type":"4"}},{"id":2470719,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-12-16T22:06:43.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":205000,"derivative":{"exercise_price":11.43,"exercise_date":"2022-12-14","expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0001127602-21-031130","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031130/form4.xml","form_type":"4"}},{"id":2470718,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2021-12-16T22:06:43.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":144000,"source":{"system":"sec-edgar","filing":"0001127602-21-031130","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031130/form4.xml","form_type":"4"}},{"id":2561293,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-23T16:35:40.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":44000,"price":5.97,"value":262680.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date."}],"balance_after":44000,"derivative":{"exercise_price":5.97,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001179110-21-008903","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008903/edgar.xml","form_type":"4"}},{"id":2561292,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-09-23T16:35:40.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The deferred share units vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-21-008903","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021008903/edgar.xml","form_type":"4"}},{"id":2762641,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-04-02T21:26:34.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":400000,"derivative":{"exercise_price":10.17,"exercise_date":"2022-03-31","expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001127602-21-012780","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221012780/form4.xml","form_type":"4"}},{"id":2762640,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true,"officer":true,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2021-04-02T21:26:34.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001127602-21-012780","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221012780/form4.xml","form_type":"4"}},{"id":2898921,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-22T21:05:00.000Z","date":"2021-01-20","kind":"grant","acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date."}],"balance_after":69000,"derivative":{"exercise_price":3.81,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0001209191-21-004845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919121004845/doc4.xml","form_type":"4"}},{"id":2898920,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Common Stock","published_at":"2021-01-22T21:05:00.000Z","date":"2021-01-20","kind":"grant","acquired":true,"shares":34500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date."}],"balance_after":183115,"source":{"system":"sec-edgar","filing":"0001209191-21-004845","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919121004845/doc4.xml","form_type":"4"}},{"id":3149742,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2020-05-14T20:36:32.000Z","date":"2020-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."}],"balance_after":40000,"derivative":{"exercise_price":5.41,"exercise_date":"2021-05-12","expiration_date":"2030-05-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001127602-20-016584","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220016584/form4.xml","form_type":"4"}},{"id":3302645,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-24T21:17:38.000Z","date":"2020-01-22","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on January 22, 2021 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date."}],"balance_after":120000,"derivative":{"exercise_price":4.72,"expiration_date":"2030-01-21","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-20-004818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919120004818/doc4.xml","form_type":"4"}},{"id":3407397,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":true}}],"security":"Non-Qualified Stock Option","published_at":"2019-09-24T20:27:41.000Z","date":"2019-09-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan."}],"balance_after":40000,"derivative":{"exercise_price":2.86,"exercise_date":"2020-09-20","expiration_date":"2029-09-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001127602-19-029012","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219029012/form4.xml","form_type":"4"}},{"id":3690510,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-22T23:20:06.000Z","date":"2019-01-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on January 17, 2020 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":10.59,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-004823","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919119004823/doc4.xml","form_type":"4"}},{"id":4100308,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-12T21:04:03.000Z","date":"2018-01-10","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on January 10, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":20.03,"expiration_date":"2028-01-09","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-003392","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919118003392/doc4.xml","form_type":"4"}},{"id":4134540,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Common Stock","published_at":"2017-12-12T21:14:56.000Z","date":"2017-12-08","kind":"sale","acquired":false,"shares":2000,"price":15.01,"value":30020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on June 19, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to\n$15.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in\nfootnote (2) to this Form 4."}],"balance_after":148615,"source":{"system":"sec-edgar","filing":"0001209191-17-065185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919117065185/doc4.xml","form_type":"4"}},{"id":4206954,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Common Stock","published_at":"2017-09-18T22:15:48.000Z","date":"2017-09-18","kind":"sale","acquired":false,"shares":2000,"price":13,"value":26000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on June 19, 2017."}],"balance_after":150615,"source":{"system":"sec-edgar","filing":"0001209191-17-053214","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919117053214/doc4.xml","form_type":"4"}},{"id":4301028,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Common Stock","published_at":"2017-05-30T20:07:18.000Z","date":"2017-05-25","kind":"sale","acquired":false,"shares":2000,"price":15.57,"value":31140.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on May 31, 2016."}],"balance_after":152615,"source":{"system":"sec-edgar","filing":"0001209191-17-036114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919117036114/doc4.xml","form_type":"4"}},{"id":4309717,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Common Stock","published_at":"2017-05-23T01:23:48.000Z","date":"2017-05-19","kind":"sale","acquired":false,"shares":2000,"price":12.14,"value":24280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016."}],"balance_after":154615,"source":{"system":"sec-edgar","filing":"0001209191-17-034534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919117034534/doc4.xml","form_type":"4"}},{"id":4497959,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Clinical Development, CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-05T13:51:34.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares underlying this option vest on January 4, 2018 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":6.33,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-17-001651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919117001651/doc4.xml","form_type":"4"}},{"id":4586269,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Clinical Development, CMO"}}],"security":"Common Stock","published_at":"2016-10-04T20:22:25.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":100,"price":7.01,"value":701.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016."}],"balance_after":156615,"source":{"system":"sec-edgar","filing":"0001209191-16-144211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919116144211/doc4.xml","form_type":"4"}},{"id":4586268,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":81309,"kind":"person","name":"Thackray Helen M.","position":1,"cik":"0001589725","reported_name":"Thackray Helen M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Clinical Development, CMO"}}],"security":"Common Stock","published_at":"2016-10-04T20:22:25.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":3900,"price":7,"value":27300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016."}],"balance_after":156715,"source":{"system":"sec-edgar","filing":"0001209191-16-144211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000120919116144211/doc4.xml","form_type":"4"}}]}